Other Information
−Removed: During the three months ended September 27, 2025, no director or officer of the Company (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted , terminated or modified a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
−Removed: Carl Russo, Chairman of the Board of Directors of the Company, is Trustee of The Crescentico Trust U/A DTD 09/06/1999.
−Removed: On April 25, 2025, The Crescentico Trust adopted a Rule 10b5-1 trading arrangement (the “10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
−Removed: The 10b5-1 Plan allows for the sale of up to 100,000 shares of Common Stock, at market prices, commencing July 2025, and continuing until May 29, 2026.
+Added: During the three months ended March 28, 2026, no director or officer of us (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted , terminated or modified a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as follows:
+Added: On February 17, 2026 , Cory Sindelar , Chief Financial Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Sindelar 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
+Added: The Sindelar 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 256,000 shares of Common Stock, at specific market prices, commencing on July 1, 2026, and continuing until all such options are exercised and the underlying shares are sold, or May 31, 2027 , whichever comes first.
+Added: On February 17, 2026 , Shane Eleniak , Chief Product Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Eleniak 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
+Added: The Eleniak 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 364,000 shares of Common Stock, at specific market prices, commencing on May 19, 2026, and continuing until all such options are exercised and the underlying shares are sold, or October 30, 2026 , whichever comes first.
+Added: On February 19, 2026 , Michael Weening , Director, President and Chief Executive Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Weening 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
+Added: The Weening 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 397,100 shares of Common Stock, at specific market prices, commencing on May 21, 2026, and continuing until all such options are exercised and the underlying shares are sold, or February 19, 2027 , whichever comes first.
Number Description
21 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: October 30, 2025 By:
+Added: April 22, 2026 By:
/s/ Michael Weening
2 unchanged sentences
(Principal Executive Officer)
−Removed: October 30, 2025 By:
+Added: April 22, 2026 By:
/s/ Cory Sindelar
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.